On June 18, Scott Wren, Wells Fargo senior global market strategist, joined CNBC’s ‘Closing Bell Overtime’ to talk about how the market sell-off is an opportunity to step in. Wren discussed the market’s performance and noted that the major averages closed down nearly a percent, with the NASDAQ faring the worst. He clarified that this reaction is not due to the lower 10-year Treasury yield but rather attributed it partly to the price of oil. He explained that a jump in oil prices, potentially to $90 or $100 a barrel, would negatively impact the market.
He suggested that after a strong run since the April lows, some investors are taking a little bit of money off the table. Wren advised against this move and recommended favoring developed international markets over emerging markets. However, Wells Fargo Investment Institute has a long-standing preference for US assets and considers them to be of better quality due to the US economy’s greater innovation compared to the European economy.
That being said, we’re here with a list of the 11 best mid cap growth stocks to invest in now.
A portfolio manager in front of their computer screen, evaluating a variety of mid-cap stocks.
Methodology
We sifted through financial media reports to compile a list of the top growth stocks trading between $2 billion and $10 billion. We then selected 11 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q1 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Best Mid Cap Growth Stocks To Invest In Now
11. Super Group Limited (NYSE:SGHC)
Market Capitalization as of June 19: $4.90 billion
Number of Hedge Fund Holders: 22
Super Group Limited (NYSE:SGHC) is one of the best mid cap growth stocks to invest in now. Earlier on June 11, BTIG analyst Clark Lampen increased the price target for Super Group to $11 from $9, while reiterating a Buy rating on the shares. This adjustment reflects BTIG’s updated financial model, which incorporates Super Group’s recent change in presentation currency and a more favorable outlook for its Sportsbook operations in FY2025 and FY2026.
In Q1 2025, Super Group’s total revenue reached an all-time high of $517 million, which marked a 25% increase year-over-year. Revenue excluding the US market was $502 million, which was up 24% year-over-year. The company’s unique monthly active customers averaged 5.4 million for the quarter, which was a 14% increase from 4.7 million in Q1 2024.
Specifically, sports betting grew 7% while casino operations saw a 23% increase. Geographically, Africa’s revenue grew by 54% due to strong performance in South Africa, Ghana, Malawi, and the successful launch in Botswana. European revenue increased by 53%, with the UK market showing particularly strong growth of 87% due to the performance of Jackpot City and Betway. Canada’s revenue also grew by 13%. However, the APEC region experienced a 13% decline due to currency weakness and the closure of non-performing markets.
Super Group Limited (NYSE:SGHC) operates as an online sports betting and gaming operator.
10. TransMedics Group Inc. (NASDAQ:TMDX)
Market Capitalization as of June 19: $4.30 billion
Number of Hedge Fund Holders: 23
TransMedics Group Inc. (NASDAQ:TMDX) is one of the best mid cap growth stocks to invest in now. On June 17, Oppenheimer increased the price target for TransMedics to $150 from $130, while maintaining an Outperform rating on the shares. This adjustment came after the OrganOx Metra device had its air transport warning removed from its label on June 2. The OrganOx Metra device is a competitor in the organ preservation market.
Despite mixed outcomes from field checks on the Metra device, OrganOx continues to receive positive feedback from the Organ Procurement Organization community. Oppenheimer expects that the OrganOx Metra device will likely gain market share in DCD/Donation after Circulatory Death liver transplants. This is attributed not necessarily to superior outcomes compared to TransMedics’ technology, but rather to a perceived strained relationship between TransMedics and the OPOs.
In Q1 2025, TransMedics achieved a record total revenue of $143.5 million, which showed a 48% year-over-year growth compared to $96.9 million in Q1 2024. Transplant services revenue specifically saw a 56% increase due to higher utilization of their OCS NOP/Organ Care System National Organ Preservation platform. TransMedics also raised its full-year 2025 revenue guidance to a range between $565 and $585 million, which represents a 30% growth at the midpoint.
TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company that transforms organ transplant therapy for end-stage organ failure patients internationally.
9. Clarivate (NYSE:CLVT)
Market Capitalization as of June 19: $2.90 billion
Number of Hedge Fund Holders: 25
Clarivate (NYSE:CLVT) is one of the best mid cap growth stocks to invest in now. Earlier on June 3, Clarivate announced a multi-year partnership with the Canadian Research Knowledge Network/CRKN. This agreement grants 55 Canadian universities expanded access to Clarivate’s Web of Science platform to foster inter-member research collaborations and enhance the accessibility of Web of Science content for all participating institutions.
The Web of Science platform is renowned for its Web of Science Core Collection, which serves as the world’s first and most trusted publisher-neutral citation index. The platform streamlines the discovery of diverse content, such as leading journals, conference papers, books, dissertations, theses, datasets, patents, preprints, awarded grants, and policy documents.
Under the new agreement, CRKN members will gain extended access to the Web of Science API, which will enable researchers to use the rich metadata for their projects. Additionally, access to the Derwent Innovations Index and the Policy Citation Index will allow members to better understand the societal impact of their research outputs.
Clarivate (NYSE:CLVT) is a global information services provider. It operates through 3 segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. CRKN is a consortium that comprises libraries and research institutions across Canada.
8. Globant (NYSE: GLOB)
Market Capitalization as of June 19: $3.88 billion
Number of Hedge Fund Holders: 31
Globant (NYSE:GLOB) is one of the best mid cap growth stocks to invest in now. Towards the end of May, Globant officially inaugurated its Middle East Regional Headquarters in Riyadh, Saudi Arabia. This milestone came less than 3 years after Globant’s initial entry into the region, which underscores its commitment to the Middle Eastern market and its ambition to lead digital reinvention through cutting-edge AI solutions and digital customer experiences.
In Q1 2025, Globant’s revenue in the Middle East & APAC region saw an 84.4% year-over-year increase. According to Gartner, IT spending in the MENA region is projected to grow by 7.4% to reach $230.7 billion in 2025. Specifically in Saudi Arabia, IDC forecasts that IT services spending will grow at a CAGR of 9% between 2022 and 2027, and ultimately reach $6.4 billion.
Located in Building 1.15 KAFD, Globant’s new headquarters also houses its third global Playground. The immersive and open space is designed to connect Middle Eastern tech leaders with future innovations through hands-on experiences blending sports, AI, and customer engagement. Previous Playgrounds have been successfully launched in São Paulo, Brazil, and Los Angeles, USA. The Riyadh hub will function as a Center of Excellence for AI and advanced digital solutions.
Globant (NYSE:GLOB) provides technology services worldwide. The company was formerly known as IT Outsourcing S.L. and changed its name to Globant S.A. in December 2012.
7. Corcept Therapeutics Incorporated (NASDAQ: CORT)
Market Capitalization as of June 19: $7.55 billion
Number of Hedge Fund Holders: 33
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best mid cap growth stocks to invest in now. Earlier on June 5, Corcept Therapeutics presented detailed results from its Phase 2 DAZALS study of dazucorilant in patients with Amyotrophic Lateral Sclerosis/ALS at the European Network to Cure ALS 2025 annual meeting. While the company announced in December 2024 that DAZALS did not meet its primary endpoint, the presentation highlighted improvement in patient survival.
The DAZALS study was a randomized, double-blind, and placebo-controlled Phase 2 trial that enrolled 249 patients with ALS. These patients were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant, or a placebo daily for 24 weeks. Patients who completed this treatment period were eligible to enroll in a long-term extension study, where all participants received 300 mg of dazucorilant. At week 24 of the study, no deaths occurred in the 83 patients who received 300 mg of dazucorilant, whereas there were 5 deaths in the 82-patient placebo group.
An exploratory analysis at the one-year mark further demonstrated a continued survival benefit, with patients randomized to 300 mg of dazucorilant living significantly longer than those who received placebo and did not switch to dazucorilant in the extension study, which showed a pronounced difference with a hazard ratio of 0.16. Dazucorilant demonstrated an acceptable safety profile throughout the study. ~92% of adverse events were mild to moderate in severity.
Corcept Therapeutics Incorporated (NASDAQ:CORT) discovers and develops medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US.
6. Moderna Inc. (NASDAQ:MRNA)
Market Capitalization as of June 19: $9.82 billion
Number of Hedge Fund Holders: 38
Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA (mRNA-1345). The vaccine is now approved for the prevention of lower respiratory tract disease/LRTD caused by RSV in individuals aged 18 to 59 years who are at increased risk.
This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved product for Moderna in the US, alongside its COVID-19 vaccine, Spikevax. The expanded approval was supported by results from Moderna’s Phase 3 study, which evaluated the vaccine’s safety and immunogenicity in 1,150 adults aged 18 to 59 years with underlying health conditions.
Moderna intends to make mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the US in time for the 2025-2026 respiratory virus season, which typically begins around November. Despite FDA approval, inclusion in national immunization schedules is determined by the US Centers for Disease Control and Prevention’s/CDC Advisory Committee on Immunization Practices. The CDC currently recommends RSV vaccines for adults aged 75 and older, and for adults aged 60 to 74 who are at increased risk.
Moderna Inc. (NASDAQ:MRNA) is a biotechnology company that provides messenger RNA medicines internationally.
5. Shift4 Payments Inc. (NYSE:FOUR)
Market Capitalization as of June 19: $8.14 billion
Number of Hedge Fund Holders: 40
Shift4 Payments Inc. (NYSE:FOUR) is one of the best mid cap growth stocks to invest in now. Earlier on June 6, Shift4 Payments, through its indirect wholly-owned subsidiary GT Holding 1 GmbH, which is a Swiss limited liability company (Merger Sub), has further extended its all-cash tender offer to acquire all outstanding shares of Global Blue Group Holding (NYSE:GB). This extension is per the transaction agreement initially dated February 16 this year, which Merger Sub joined on February 25.
The tender offer is subject to several conditions, including regulatory approvals in certain jurisdictions and other customary closing conditions. Notably, the minimum tender condition, set at 90%, has already been met, with ~96.95% of Global Blue’s issued and outstanding shares having been validly tendered and not withdrawn as of June 5. Global Blue’s board of directors has unanimously recommended that all shareholders tender their shares into the offer.
The transaction is still expected to close by Q3 2025, as previously announced. The tender offer will now remain open until one minute after 11:59 p.m. (NYC time) on June 23. It may be extended again if necessary, as the parties await the remaining regulatory approvals. Shareholders who have already tendered their shares do not need to take any further action.
Shift4 Payments Inc. (NYSE:FOUR) provides software and payment processing solutions in the United States and internationally. Global Blue Group Holding (NYSE:GB) provides technology and payments solutions for merchants, acquirers, customs, authorities, travelers, shoppers, and guests.
4. Protagonist Therapeutics Inc. (NASDAQ:PTGX)
Market Capitalization as of June 19: $3.34 billion
Number of Hedge Fund Holders: 40
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, Protagonist Therapeutics and Takeda Pharmaceutical Company Limited (NYSE:TAK) announced the full 32-week results from their Phase 3 VERIFY study of rusfertide in patients with polycythemia vera/PV. The detailed results were presented as a late-breaking oral presentation/LBA3 at the 61st ASCO Annual Meeting Plenary Session on June 1.
The study successfully met its primary endpoint and all key secondary endpoints. PV is a blood disorder characterized by the overproduction of red blood cells, which can lead to increased blood viscosity and potentially life-threatening thrombotic events like stroke, deep vein thrombosis, and pulmonary embolism. Patients often experience debilitating symptoms such as severe fatigue, difficulty concentrating, night sweats, and pruritus.
The primary treatment goal in PV is to achieve and maintain controlled hematocrit levels below 45% to prevent thrombotic events and alleviate symptoms. However, many patients struggle to achieve adequate control with the current standard of care treatments. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic that aims to regulate iron homeostasis and red blood cell production to control hematocrit levels in PV patients.
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide therapeutics for hematology & blood disorders, and inflammatory & immunomodulatory diseases. Takeda Pharmaceutical Company Limited (NYSE:TAK) researches, develops, manufactures, markets, and out-licenses pharmaceutical products in Japan and internationally.
3. Lantheus Holdings Inc. (NASDAQ:LNTH)
Market Capitalization as of June 19: $5.46 billion
Number of Hedge Fund Holders: 43
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the best mid cap growth stocks to invest in now. Earlier on June 11, Lantheus Holdings announced that new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging/SNMMI Annual Meeting. The meeting is scheduled to take place from June 21-24, 2025, in New Orleans, LA.
An oral presentation titled ‘Optimized Production and Quality Control of the FAP imaging Agent [64Cu]LNTH-1363S’ will be given by Gengyang Yuan of Lantheus on June 24 during Session Number SS39. Three poster presentations are also planned.
On June 22, during Session Number MTA03, Amir Iravani from the University of Washington will present ’18F-Piflufolastat PET/CT in Patients with Biochemically Recurrent Prostate Cancer: a CONDOR Sub-analysis of Positive Predictive Value in the Prostate/Prostatic Bed Stratified by PSA.’
On June 23, Ida Sonni from the University of California, Los Angeles, will present ‘First Clinical Evaluation of 68Ga-LNTH-1363S, a Novel FAP-Targeting Radiopharmaceutical for PET Imaging: Physiological Biodistribution and Tumor Uptake in Cancer Patients’ during Session Number MTA06.
Finally, June 24, Gyu Seong Heo from the Department of Radiology, Washington University, will present ‘Preclinical assessment of 64Cu-LNTH-1363S for FAP PET imaging in mouse models of myocardial infarction’ during Session Number SS27.
Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic & therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
2. Qorvo Inc. (NASDAQ:QRVO)
Market Capitalization as of June 19: $7.47 billion
Number of Hedge Fund Holders: 45
Qorvo Inc. (NASDAQ:QRVO) is one of the best mid cap growth stocks to invest in now. As May was ending, Qorvo introduced 2 new hybrid power doubler amplifiers, the QPA3311 and QPA3316. These devices are designed to bolster Qorvo’s DOCSIS 4.0 portfolio for broadband cable networks to deliver high-speed internet and video services over existing cable systems.
The announcement was made to support the industry’s transition towards Unified DOCSIS and smart amplifier architectures for greater visibility, efficiency, and adaptability in hybrid fiber-coax systems. The QPA3311 and QPA3316 amplifiers are optimized for downstream operations up to 1.8 GHz. They offer higher total composite power and improved signal integrity, which helps reduce cascade requirements and enhance end-of-line performance.
This innovation will lead to lower infrastructure costs by eliminating the need for expensive booster amplifiers. The QPA3311 is suitable for power-efficient designs requiring strong end-of-line performance. The QPA3316 is designed for high-output nodes needing maximum downstream performance.
Qorvo Inc. (NASDAQ:QRVO) develops and commercializes technologies and products for wireless, wired, and power markets worldwide.
1. Sarepta Therapeutics Inc. (NASDAQ:SRPT)
Market Capitalization as of June 19: $2.04 billion
Number of Hedge Fund Holders: 47
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta Therapeutics announced that the US FD has granted Platform Technology Designation to the rAAVrh74 viral vector. The vector is utilized in SRP-9003 (bidridistrogene xeboparvovec), which is Sarepta’s investigational gene therapy for the treatment of limb-girdle muscular dystrophy type 2E/R4 (or LGMD2E/R4), also known as beta-sarcoglycanopathy.
The designation is the first of its kind awarded by the FDA and marks a recognition of the reproducibility and adaptability of this technology across multiple therapeutic programs. The Platform Technology Designation program, which was conceived in 2023 with draft guidance rolled out in May 2024, aims to streamline drug development, manufacturing, and review processes for drug product applications, especially for rare diseases, by allowing sponsors to use prior data from designated technologies.
The rAAVrh74 viral vector is a key component in several of Sarepta’s gene therapy programs, including Elevidys, an already FDA-approved gene therapy for Duchenne muscular dystrophy. It is also part of SRP-9003, which delivers a full-length beta-sarcoglycan transgene using the MHCK7 promoter, chosen for its expression in the heart, a critical factor for LGMD2E/R4 patients who often face pulmonary or cardiac complications. The designation allows Sarepta to use evidence previously gathered from studies involving the vector in future INDs, NDAs, or BLAs.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
While we acknowledge the potential of SRPT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SRPT and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None.
